Compare CRVL & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVL | TLX |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 1995 | 2024 |
| Metric | CRVL | TLX |
|---|---|---|
| Price | $86.46 | $9.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $19.90 |
| AVG Volume (30 Days) | 133.7K | ★ 320.2K |
| Earning Date | 11-03-2026 | 10-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.94 | N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $958,527,000.00 | N/A |
| Revenue This Year | N/A | $16.59 |
| Revenue Next Year | N/A | $13.64 |
| P/E Ratio | ★ $66.00 | $150.33 |
| Revenue Growth | ★ 7.03 | N/A |
| 52 Week Low | $44.83 | $6.28 |
| 52 Week High | $89.76 | $13.11 |
| Indicator | CRVL | TLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.89 | 43.03 |
| Support Level | $56.81 | $8.69 |
| Resistance Level | $89.76 | $9.70 |
| Average True Range (ATR) | 2.75 | 0.22 |
| MACD | -0.18 | 0.08 |
| Stochastic Oscillator | 68.78 | 43.81 |
CorVel Corp applies technology including artificial intelligence, machine learning, and natural language processing to enhance the managing of episodes of care and the related health care costs. It partners with employers, third-party administrators, insurance companies, and government agencies in managing worker's compensation and health, auto, and liability services. The company's solutions combine integrated technologies with a human touch providing services that include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care, and medicare services.
Telix is a developer of radiopharmaceuticals. Radiopharmaceuticals are specialized drugs containing radioactive isotopes, which are used in both diagnosing and treating cancer. At low doses, these drugs bind to a specific cancer cell and can be visualized through PET imaging. With high doses, they can deliver targeted treatment. Telix has a pipeline of both diagnostics and therapeutics in development. Its pipeline is focused on urologic oncology (prostate, kidney and bladder), neuro-oncology (glioma), musculoskeletal oncology and hematology. Currently, most of the firm's revenue comes from its Illuccix prostate cancer imaging/diagnostic agent.